NIH seeks licensees for T-cell immunotherapy invention
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
NIH is offering a government-owned invention for licensing that could improve T-cell immunotherapy by targeting three inhibitory proteins: SIT1, LAX1, and TRAT1. Early mouse studies suggest that removing or disabling these proteins can strengthen T-cell signaling and increase tumor-killing activity. Biotech companies, cancer therapy developers, immunology researchers, and investors in cell therapy should watch this opportunity. The technology is still pre-clinical, with human T-cell experiments underway, so the practical next step is licensing, further validation, and development toward therapies for cancer and possibly infectious or autoimmune diseases.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- NIH is seeking licensees to develop a government-owned T-cell immunotherapy invention.
- The technology targets SIT1, LAX1, and TRAT1 proteins to potentially increase T-cell activity against tumors.
- The invention is pre-clinical, with a PCT patent application filed and human T-cell validation underway.